Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis

Abstract Background The oral anti‐janus kinase 1 inhibitor upadacitinib has shown a good efficacy–safety profile in the treatment of moderate‐to‐severe atopic dermatitis (AD) in clinical trials; however, few data from real clinical practice have been published so far. Objectives To evaluate the effi...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Ana Batalla, Hae Jin Suh‐Oh, Gregorio Carretero Hernández, Javier Miquel‐Miquel, Rafael Botella‐Estrada, Antonio Martorell‐Calatayud, Virginia Sanz‐Motilva, Ignasi Figueras‐Nart, Angeles Flórez
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Wiley 2023-09-01
סדרה:	JEADV Clinical Practice
נושאים:	atopic dermatitis treatment upadacitinib
גישה מקוונת:	https://doi.org/10.1002/jvc2.179
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!